The content on this site is intended for healthcare professionals only
ESMO 2021: PARPi data and their role in mono/combination therapies
Dr Neal Shore, Prof Fred Saad, Prof Eleni Efstathiou, Prof Andrew Armstrong
29 Sep 2021
ESMO 2021: Updates in hormone-sensitive prostate cancer
Prof Eleni Efstathiou, Prof Axel Merseburger, Prof Nicolas Mottet, Dr Elena Cast...
28 Sep 2021
Quality of life and safety in novel therapies for prostate cancer
Prof Heather Payne, Prof Alicia Morgans and Prof Bertrand Tombal
24 Sep 2021
Enzalutamide plus androgen deprivation therapy prolongs survival in men with met...
Prof Andrew Armstrong - Duke University, Durham, USA
24 Sep 2021
Adding abiraterone acetate plus prednisolone to standard therapy lengthens survi...
Prof Nick James - The Institute of Cancer Research, London, UK
23 Sep 2021
Welcome to APCCC 2021
Prof Silke Gillessen and Prof Aurelius Omlin
23 Sep 2021
ESMO 2021 Roundup
Dr Bishal Gyawali - Queen's University, Kingston, Canada
22 Sep 2021
PARP inhibitors in prostate cancer: Case based testing and clinical decisions
Dr Neal Shore and Prof Fred Saad
20 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 4
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
20 Sep 2021
Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25% reduct...
Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France
19 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 3
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
19 Sep 2021
STAR: First-line sunitinib or pazopanib for locally advanced and/or metastatic r...
Prof Janet Brown - University of Sheffield, Sheffield, United Kingdom
19 Sep 2021